These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38265522)

  • 1. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
    Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
    Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
    Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
    Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supratentorial and Infratentorial Ependymoma.
    Myseros JS
    Adv Tech Stand Neurosurg; 2024; 53():93-118. PubMed ID: 39287805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.
    Baroni LV; Sundaresan L; Heled A; Coltin H; Pajtler KW; Lin T; Merchant TE; McLendon R; Faria C; Buntine M; White CL; Pfister SM; Gilbert MR; Armstrong TS; Bouffet E; Kumar S; Taylor MD; Aldape KD; Ellison DW; Gottardo NG; Kool M; Korshunov A; Hansford JR; Ramaswamy V
    Neuro Oncol; 2021 Aug; 23(8):1360-1370. PubMed ID: 33580238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of histopathological ependymoma variants.
    Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
    Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
    Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
    Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
    Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
    Neyazi S; Yamazawa E; Hack K; Tanaka S; Nagae G; Kresbach C; Umeda T; Eckhardt A; Tatsuno K; Pohl L; Hana T; Bockmayr M; Kim P; Dorostkar MM; Takami T; Obrecht D; Takai K; Suwala AK; Komori T; Godbole S; Wefers AK; Otani R; Neumann JE; Higuchi F; Schweizer L; Nakanishi Y; Monoranu CM; Takami H; Engertsberger L; Yamada K; Ruf V; Nomura M; Mohme T; Mukasa A; Herms J; Takayanagi S; Mynarek M; Matsuura R; Lamszus K; Ishii K; Kluwe L; Imai H; von Deimling A; Koike T; Benesch M; Kushihara Y; Snuderl M; Nambu S; Frank S; Omura T; Hagel C; Kugasawa K; Mautner VF; Ichimura K; Rutkowski S; Aburatani H; Saito N; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):22. PubMed ID: 38265489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
    Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
    Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging features to distinguish posterior fossa ependymoma subgroups.
    Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.
    Ramaswamy V; Hielscher T; Mack SC; Lassaletta A; Lin T; Pajtler KW; Jones DT; Luu B; Cavalli FM; Aldape K; Remke M; Mynarek M; Rutkowski S; Gururangan S; McLendon RE; Lipp ES; Dunham C; Hukin J; Eisenstat DD; Fulton D; van Landeghem FK; Santi M; van Veelen ML; Van Meir EG; Osuka S; Fan X; Muraszko KM; Tirapelli DP; Oba-Shinjo SM; Marie SK; Carlotti CG; Lee JY; Rao AA; Giannini C; Faria CC; Nunes S; Mora J; Hamilton RL; Hauser P; Jabado N; Petrecca K; Jung S; Massimi L; Zollo M; Cinalli G; Bognár L; Klekner A; Hortobágyi T; Leary S; Ermoian RP; Olson JM; Leonard JR; Gardner C; Grajkowska WA; Chambless LB; Cain J; Eberhart CG; Ahsan S; Massimino M; Giangaspero F; Buttarelli FR; Packer RJ; Emery L; Yong WH; Soto H; Liau LM; Everson R; Grossbach A; Shalaby T; Grotzer M; Karajannis MA; Zagzag D; Wheeler H; von Hoff K; Alonso MM; Tuñon T; Schüller U; Zitterbart K; Sterba J; Chan JA; Guzman M; Elbabaa SK; Colman H; Dhall G; Fisher PG; Fouladi M; Gajjar A; Goldman S; Hwang E; Kool M; Ladha H; Vera-Bolanos E; Wani K; Lieberman F; Mikkelsen T; Omuro AM; Pollack IF; Prados M; Robins HI; Soffietti R; Wu J; Metellus P; Tabori U; Bartels U; Bouffet E; Hawkins CE; Rutka JT; Dirks P; Pfister SM; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Ellison DW; Taylor MD
    J Clin Oncol; 2016 Jul; 34(21):2468-77. PubMed ID: 27269943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct relapse pattern across molecular ependymoma types.
    Obrecht-Sturm D; Schoof M; Eckhardt A; Mynarek M; Gilbert MR; Aldape K; Armstrong TS; Ramaswamy V; Bockmayr M; von Hoff K; Fleischhack G; Adolph JE; Tippelt S; Pfister SM; Pajtler K; Sturm D; Drexler R; Ricklefs FL; Stepien N; Gojo J; Pietsch T; Warmuth-Metz M; Kortmann R; Timmermann B; Haberler C; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Aug; ():. PubMed ID: 39171767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
    Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional profiling of paediatric ependymomas identifies prognostically significant groups.
    Łastowska M; Matyja E; Sobocińska A; Wojtaś B; Niemira M; Szałkowska A; Krętowski A; Karkucińska-Więckowska A; Kaleta M; Ejmont M; Tarasińska M; Perek-Polnik M; Dembowska-Bagińska B; Pronicki M; Grajkowska W; Trubicka J
    J Pathol Clin Res; 2021 Nov; 7(6):565-576. PubMed ID: 34314101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.